Dendritic cell co-stimulatory molecules

Patent metadata

Field	Value
Publication number	US-9370565-B2
Application number	US-201314068966-A
Country	US
Kind code	B2
Filing date	Oct 31, 2013
Priority date	Apr 28, 2000
Publication date	Jun 21, 2016
Grant date	Jun 21, 2016

Abstract

A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tumor and anti-viral immunity.

First claim

What is claimed is:

1. A method of treating a human subject having cancer comprising administering to the subject:
a) a tumor-reducing regimen of chemotherapy, irradiation or surgical resection; and
b) a pharmaceutical composition comprising a fusion protein comprising a first fusion partner consisting of amino acids 20-221 of SEQ ID NO:2 and a second fusion partner consisting of the hinge, CH2 and CH3 regions of a human immunoglobulin C 1 chain.

2. The method of claim 1 wherein the fusion protein comprises a linker between the first and second fusion partners.

3. The method of claim 1 wherein the first fusion partner is directly linked to the second fusion partner.

4. The method of claim 1 , wherein the fusion protein is administered as a dimer formed by covalent bonding of Cys residues in at least one of said CH2 and CH3.

5. The method of claim 1 wherein the cancer is a melanoma.

6. The method of claim 1 wherein the cancer is a carcinoma.

7. The method of claim 6 wherein the carcinoma is hepatocellular carcinoma.

8. The method of claim 6 wherein the carcinoma is cervical cancer.

9. The method of claim 8 wherein the cervical cancer is caused by human papillomavirus (HPV).

10. The method of claim 6 wherein the subject has a chronic human viral infection.

11. The method of claim 10 wherein the chronic human viral infection is due to a virus selected from the group consisting of hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Epstein Barr virus (EBV) and herpes simplex virus (HSV).

12. The method of claim 6 wherein the subject has a non-viral infectious disease.

13. The method of claim 2 wherein the pharmaceutical composition is administered to the human in an effective amount to induce, enhance, increase, or potentiate an immune response against the cancer.

14. The method of claim 2 further comprising administering to the human a general immunostimulatory agent or adjuvant.

15. The method of claim 14 wherein the general immunostimulatory agent or adjuvant is part of the pharmaceutical composition.

16. A method of treating a human subject having cancer comprising administering to the subject a pharmaceutical composition comprising a fusion protein comprising a first fusion partner consisting of amino acids 20-221 of SEQ ID NO:2 and a second fusion partner consisting of the hinge, CH2 and CH3 regions of a human immunoglobulin C 1 chain in combination with a second treatment selected from the group consisting of chemotherapy, irradiation, and surgical resection.

17. The method of claim 16 wherein the pharmaceutical composition is administered to the subject after treatment of the subject with the chemotherapy, irradiation, or surgical resection.

18. The method of claim 16 wherein the pharmaceutical composition is administered to the subject before treatment of the subject with the chemotherapy, irradiation, or surgical resection.

19. The method of claim 16 wherein the pharmaceutical composition is administered to the subject simultaneously with the chemotherapy, irradiation, or surgical resection.

20. A method of increasing an immune response in a human subject having cancer comprising administering to the subject a pharmaceutical composition comprising a fusion protein comprising a first fusion partner consisting of amino acids 20-21 of SEQ ID NO:2 and a second fusion partner consisting of the hinge, CH2 eand CH3 regions of a human immunoglobulin C 1 chain in combination with a second treatment selected from the group consisting of a tumor-reducing regimen of chemotherapy, irradiation, and surgical resection.

21. The method of claim 20 wherein the immune response is against the cancer.

22. The method of claim 21 wherein the cancer is a melanoma or a carcinoma.

Assignees

• Univ Johns Hopkins

Inventors

• Pardoll Drew M
• Tsuchiya Haruo
• Gorski Kevin S
• Tseng Su-Yi

Classifications

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title